Search Results
Jun 11, 2026, 21:35 ET AES Announces Pricing of $1 Billion of Senior Notes in Public Offering
Analysis" in AES' 2025 Annual Report on Form 10-K, in AES' Quarterly Report on Form 10-Q for the quarter ended March 31, 2026 and in any subsequent reports filed with the SEC. Potential investors are encouraged to read AES' filings to learn more about the risk factors associated with AES' business. AES undertakes
More news about: The AES Corporation
Jun 11, 2026, 12:00 ET AES Investors Have Opportunity to Join The AES Corporation Fraud Investigation with the Schall Law Firm
Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of The AES Corporation ("AES" or "the Company") (NYSE: AES) for violations of the securities laws.
More news about: The Schall Law Firm
Jun 10, 2026, 10:20 ET Futuri Launches TopLine Enterprise: The Revenue Intelligence Platform That Turns One Sales Rep Into Five.
in 90 days2.1x pipeline growth in a single quarter$2.4M in new business over six monthsDeals closing 50-70% fasterAEs reclaim 14 hours of those 18 hours weekly
More news about: Futuri Media
Jun 10, 2026, 10:01 ET Developmental and Epileptic Encephalopathies Market to Register Immense Growth at a CAGR of 11.7% During the Forecast Period (2026-2036) Due to the Launch of Next-Generation Gene and Targeted Therapies | DelveInsight
2025, Lundbeck announces positive Phase II long–term data for bexicaserin in rare childhood–onset epilepsies, at the 2025 American Epilepsy Society (AES) Annual Meeting.What are Developmental and Epileptic Encephalopathies?Developmental and epileptic encephalopathies (DEEs)
More news about: DelveInsight Business Research, LLP
Jun 10, 2026, 09:00 ET Hoxhunt 2026 Research Reports Reveal a Surge in Phishing Attacks, Reinforcing the Need for Human-Centric Cybersecurity
Qualcomm, Docusign, Nokia, AES, Air Asia, and E.on, and partners with leading global cybersecurity companies such as Microsoft and Deloitte.Media ContactChristian
More news about: Hoxhunt
Jun 10, 2026, 05:30 ET Fearn Raises $5.5 Million Seed to End the Two-Tier Patent System
generative AI. Enterprise customers can choose customer-hosted VPC, single-tenant VPC, or multi-tenant VPC deployment; all customer data is held under AES-256 encryption, with SOC 2, ISO 27001, ISO 27701, and GDPR compliance.Fearn is already trusted by engineers and scientists at companies including
More news about: Fearn
Jun 09, 2026, 12:31 ET Pine County History Museum is Achieving Energy Independence with All Energy Solar
and domestic sourcing benefits, AES has helped the museum devise a plan to greatly accelerate the project's return on the investment. For more information or to learn how your business or home can benefit from using solar energy, connect with All Energy Solar. AES provides a full-service solar solution
More news about: All Energy Solar, Inc
Jun 08, 2026, 09:02 ET AES Investors Have Opportunity to Join The AES Corporation Fraud Investigation with the Schall Law Firm
Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of The AES Corporation ("AES" or "the Company") (NYSE: AES) for violations of the securities laws.
More news about: The Schall Law Firm
Jun 08, 2026, 08:00 ET Argo Biopharma to Present Positive Phase II Updated Results of siRNA Therapeutic BW-20805 for HAE at the EAACI 2026 Congress
with sustained robust suppression.BW-20805 was well tolerated among 18 patients across 3 treatment groups, There were no drug-related severe AEs or SAEs, No TEAE leading to study discontinuation or death were reported. Most common AE was injection site reaction, which was mild, and transient without
More news about: Argo Biopharmaceutical Co., Ltd
Jun 07, 2026, 20:10 ET Ascletis Reinforces Its Differentiated Obesity Portfolio at American Diabetes Association (ADA) 2026 Scientific Sessions, Showcasing ASC30 Clinical Data and Exciting Preclinical Findings from ASC37 and ASC39
all GI adverse events (AEs) were grade 1 (mild) and grade 2 (moderate) in severity, and there were no grade 3 (severe) or above GI AEs. There were no drug-related AEs of grade 3 (severe) or higher. No drug-related serious AEs (SAEs). The treatment discontinuation rates due to AEs were 7.3%, 7.5%, and
More news about: Ascletis Pharma Inc.
Jun 07, 2026, 17:30 ET Novo Nordisk's CagriSema 2.4 mg / 2.4 mg demonstrated significant reduction in HbA1c and weight across multiple studies in the REIMAGINE program presented at ADA 2026
most commonly reported adverse events (AEs) were gastrointestinal (GI)-related, occurring in 33/62 (53%) participants in the CagriSema 2.4 mg/2.4 mg group, 28/63 (44%) participants in the CagriSema 1 mg/1 mg group, and 13/64 (20%) participants in the placebo group. AEs leading to trial product discontinuation
More news about: NOVO NORDISK INC.
Jun 06, 2026, 13:00 ET Novo Nordisk to present new data on Wegovy® across a wide range of cardiometabolic conditions at the American Diabetes Association's 2026 Scientific Sessions
asthma were followed for asthma-related AEs/SAEs. A total of 1190 patients had asthma. Overall, patients with established cardiovascular disease, asthma and obesity or overweight treated with semaglutide injection 2.4 mg had a lower incidence of asthma-related AEs/SAEs (n=27) versus placebo (n= 46) [HR
More news about: NOVO NORDISK INC.
Jun 05, 2026, 19:30 ET Novo Nordisk's investigational zenagamtide shows significant A1C reductions with up to 14.6% weight loss in adults with type 2 diabetes--presented at ADA 2026
baseline to week 36 in: time in range; body weight; systolic blood pressure; high-sensitivity C-reactive protein; lipids; and the number of adverse events (AEs) from baseline to end of trial (week 40).About type 2 diabetesType 2 diabetes is a chronic condition that affects how the body
More news about: NOVO NORDISK INC.
Jun 03, 2026, 09:00 ET Joyce A. Cramer to Receive Lifetime Accelerator Award for Transformative Contributions to Clinical Research and Epilepsy Innovation
preference and other patient-reported outcomes, and pharmaco-economics.Her many honors include the ILAE Epilepsy Ambassador Award, the AES Service Award, the AES Penry Award for Excellence in Epilepsy Care, the ISPOR Distinguished Service Award, and the International Research Promotion Council Award
More news about: Epilepsy Foundation
Jun 02, 2026, 10:23 ET Stelexis BioSciences Announces Positive Phase 1 Data for Eganelisib in Relapsed/Refractory AML and Higher-Risk MDS in an Oral Presentation at ASCO 2026
were disease-related rather than treatment-related, consistent with the underlying patient population. Treatment-related AEs were predominantly low-grade with no Grade 5 related AEs. Of note, no eganelisib-related SAEs were observed and no patient discontinued treatment due to an eganelisib-related AE.Published
More news about: Stelexis BioSciences, Inc.
Jun 02, 2026, 07:00 ET New High-grade Lithium, Caesium, and Tantalum Pegmatite Discoveries in Surface Exploration Works
Burnaby, BC, where the samples were homogenized and subsequently analyzed for multi-element (including Li and Ta) using sodium peroxide fusion with ICP-AES/MS finish (codes GE_ICP91A50 and GE_IMS91A50). Overlimits for Cs were completed at SGS Canada's laboratory in Lakefield, ON, by borate-fusion XRF (code
More news about: PMET Resources Inc.
Jun 01, 2026, 07:30 ET Biohaven Reports First-in-Human Dosing of Oral PKM2 Modulator, BHV-8100, Targeting Metabolic Restoration and Immunomodulation
once-daily dosingAchieved projected therapeutic exposuresDemonstrated well tolerated profile at projected therapeutic exposures, with most AEs being mild and spontaneously resolvingBharat Awsare, M.D., Executive Medical Director, Clinical Development at Biohaven stated, "The initiation
More news about: Biohaven Ltd.
May 31, 2026, 20:00 ET 2026 ASCO | Innovent Presents Long-Term Follow-up Results from the PoC Study of IBI363 (TAK-928) (PD-1/IL-2α-bias bispecific fusion protein), Showing Robust Survival Benefits in Advanced Immunotherapy-Resistant Non-Small Cell Lung Cancer
3.7% ≥grade 3), anemia (46.3%, 4.4% ≥grade 3), and rash (39.0%, 8.8% ≥grade 3), which were mostly controllable and manageable with mild-to-moderate AEs. No new safety signals were observed.Professor Jianya Zhou, The First Affiliated Hospital, School of Medicine, Zhejiang University, commented:
More news about: Innovent Biologics
May 31, 2026, 17:36 ET Servier to Present Extended Follow-Up Results from the Phase 3 INDIGO Trial Showing Durable and Sustained Treatment Benefits of VORANIGO® (vorasidenib) at ASCO 2026
seizures was observed in patients treated with VORANIGO.The safety profile of VORANIGO was tolerable with mainly low-grade adverse events (AEs) and consistent with previously reported data. The most commonly reported Grade ≥3 or worse treatment-emergent adverse events (TEAEs) were increased
More news about: Servier Pharmaceuticals
May 31, 2026, 08:01 ET Lilly's Retevmo (selpercatinib) demonstrated an 83% reduction in the risk of disease recurrence or death as adjuvant therapy for people with early-stage RET fusion-positive lung cancer
was generally consistent with previously reported trials in the selpercatinib development program. The most common Grade 3 or higher adverse events (AEs) were increased alanine aminotransferase (ALT) (17% in the selpercatinib group versus 1% in the placebo group) and increased aspartate aminotransferase
More news about: Eli Lilly and Company
May 29, 2026, 09:30 ET Acer Unveils Sub-1kg TravelMate P6 14 AI Business Laptop with New Acer Comfort Touch Design for Premium Luxury on the Move
2-in-1 convertible powered by the new Intel Core Series 3 processors, offering a WUXGA 1920 x 1200 touchscreen, a user-facing webcam, garaged Wacom AES 2.0 stylus, Wi-Fi 7, and built-in security features.Ideal for SMBs, the Acer TravelMate X2 15 and TravelMate X2 14 are also powered by
More news about: Acer
May 29, 2026, 09:00 ET Acer Launches New Swift Air 14 Powered by Latest Intel Core Series 3 Processors
glass display features a 120 Hz refresh rate for smoother video and graphics. The screen also features multi-touch and an Acer Active Stylus with Wacom AES 2.0 support for convenient navigation, responsive access to apps, and precise pen interactions for creating and signing documents and more. The Acer
More news about: Acer
May 29, 2026, 08:00 ET AbbVie Announces European Commission Authorization of Expanded Label for VENCLYXTO® (venetoclax) to Include Additional Combinations in Previously Untreated Chronic Lymphocytic Leukemia
therapy.8The most common treatment-emergent AEs in patients who received VENCLYXTO plus ibrutinib were diarrhea (62%), nausea (43%), neutropenia (42%) and arthralgia (33%); AEs were primarily grade 1 or 2 in severity. The most common grade 3/4 AEs were neutropenia (33%), hypertension (6%) and neutrophil
More news about: AbbVie
May 29, 2026, 08:00 ET AbbVie Announces European Commission Authorization of Expanded Label for VENCLYXTO® (venetoclax) to Include Additional Combinations in Previously Untreated Chronic Lymphocytic Leukemia
therapy.8The most common treatment-emergent AEs in patients who received VENCLYXTO plus ibrutinib were diarrhea (62%), nausea (43%), neutropenia (42%) and arthralgia (33%); AEs were primarily grade 1 or 2 in severity. The most common grade 3/4 AEs were neutropenia (33%), hypertension (6%) and neutrophil
More news about: AbbVie
May 28, 2026, 09:01 ET Acer Broadens Portfolio with Two New Laptops Powered by the Latest Snapdragon Processors
thin-and-light design delivers versatile usage in any environment; it offers military-grade durability and comes with an Acer Active Stylus 420 (Wacom AES 2.0 Protocol) for intuitive control on its touchscreen display.As a Copilot+ PC, it offers unique experiences[1] on Windows 11, complemented
More news about: Acer